HopeStage
Back to all studies
TerminatedNCT03210480

SALT Study (Switching to the Administration of Lithium Slow -Release Treatment)

Medication studyAges 18–65ItalyBipolarity
The study in practice

Understand this study

Who could participate?

This study is for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Listed locations
Orbetello and 5 more locationsSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: March 28, 2017
Recruitment status
Terminated
Enrollment listed in the registry
85
Sponsor
Aziende Chimiche Riunite Angelini Francesco S.p.A
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Italy
Age range
From 18 Years to 65 Years
Official registry ID
NCT03210480
Official title
Show the full official title

Clinical Evaluation of Switching to Lithiofor® (Lithium Sulphate Slow -Release, Li-SR Tablets) From Carbolithium® (Lithium Carbonate Immediate-Release, Li-IR, Capsules) in Bipolar Patients, Poorly Tolerant to Lithium Immediate-release Treatment.

Recruitment & locations

Terminated

Orbetello · Bergamo · Genova

3 more locations
  • Pisa
  • Roma
  • Siena

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Aziende Chimiche Riunite Angelini Francesco S.p.A.

Does this study involve medication?

Yes. The study involves medication, including Lithium sulphate prolonged-release 660 mg and Lithium carbonate immediate-release 150 mg and 300 mg.

Who can participate?

This study is for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies